{"id":"https://openalex.org/W2797228551","doi":"https://doi.org/10.1016/j.jaip.2018.04.003","title":"Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis","display_name":"Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis","publication_year":2018,"publication_date":"2018-04-12","ids":{"openalex":"https://openalex.org/W2797228551","doi":"https://doi.org/10.1016/j.jaip.2018.04.003","mag":"2797228551","pmid":"https://pubmed.ncbi.nlm.nih.gov/29655772"},"language":"en","primary_location":{"id":"doi:10.1016/j.jaip.2018.04.003","doi":"https://doi.org/10.1016/j.jaip.2018.04.003","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jaip.2018.04.003","pdf_url":"http://www.jaci-inpractice.org/article/S2213219818302733/pdf","source":{"id":"https://openalex.org/S2754868259","display_name":"The Journal of Allergy and Clinical Immunology In Practice","issn_l":"2213-2198","issn":["2213-2198","2213-2201"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Allergy and Clinical Immunology: In Practice","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.jaci-inpractice.org/article/S2213219818302733/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5014026287","display_name":"Marta Ferrer","orcid":"https://orcid.org/0000-0001-8495-1302","observed_orcids":["https://orcid.org/0000-0001-8495-1302"]},"institutions":[{"id":"https://openalex.org/I4210112085","display_name":"Navarre Institute of Health Research","ror":"https://ror.org/023d5h353","country_code":"ES","type":"education","lineage":["https://openalex.org/I4210112085"]},{"id":"https://openalex.org/I4210135003","display_name":"Clinica Universidad de Navarra","ror":"https://ror.org/03phm3r45","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210135003"]}],"countries":["ES"],"is_corresponding":true,"raw_author_name":"Marta Ferrer","raw_affiliation_strings":["Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), RETIC de Asma, Reacciones adversas y Al\u00e9rgicas (ARADYAL), Pamplona, Spain. Electronic address: mferrerp@unav.es","Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), RETIC de Asma, Reacciones adversas y Al\u00e9rgicas (ARADYAL), Pamplona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), RETIC de Asma, Reacciones adversas y Al\u00e9rgicas (ARADYAL), Pamplona, Spain. Electronic address: mferrerp@unav.es","institution_ids":["https://openalex.org/I4210112085","https://openalex.org/I4210135003"]},{"raw_affiliation_string":"Department of Allergy and Clinical Immunology, Clinica Universidad de Navarra, Instituto de Investigaci\u00f3n Sanitaria de Navarra (IdiSNA), RETIC de Asma, Reacciones adversas y Al\u00e9rgicas (ARADYAL), Pamplona, Spain","institution_ids":["https://openalex.org/I4210112085","https://openalex.org/I4210135003"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062536923","display_name":"Ana Maria Gim\u00e9nez\u2010Arnau","orcid":"https://orcid.org/0000-0001-5434-7753","observed_orcids":["https://orcid.org/0000-0001-5434-7753","https://orcid.org/0009-0009-6824-7687","https://orcid.org/0000-0002-3898-0652"]},"institutions":[{"id":"https://openalex.org/I123044942","display_name":"Universitat Aut\u00f2noma de Barcelona","ror":"https://ror.org/052g8jq94","country_code":"ES","type":"education","lineage":["https://openalex.org/I123044942"]},{"id":"https://openalex.org/I170486558","display_name":"Universitat Pompeu Fabra","ror":"https://ror.org/04n0g0b29","country_code":"ES","type":"education","lineage":["https://openalex.org/I170486558"]},{"id":"https://openalex.org/I4210130874","display_name":"Hospital Del Mar","ror":"https://ror.org/03a8gac78","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210130874"]},{"id":"https://openalex.org/I4210133106","display_name":"Parc de Salut","ror":"https://ror.org/032exky44","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210133106"]},{"id":"https://openalex.org/I4210156109","display_name":"Hospital del Mar Research Institute","ror":"https://ror.org/042nkmz09","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4210156109","https://openalex.org/I4387153040"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Ana Gim\u00e9nez-Arnau","raw_affiliation_strings":["Dermatology Department, Hospital del Mar-Parc de Salut Mar, IMIM, Universitat Aut\u00f2noma y Universitat Pompeu Fabra, Barcelona, Spain"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dermatology Department, Hospital del Mar-Parc de Salut Mar, IMIM, Universitat Aut\u00f2noma y Universitat Pompeu Fabra, Barcelona, Spain","institution_ids":["https://openalex.org/I123044942","https://openalex.org/I170486558","https://openalex.org/I4210130874","https://openalex.org/I4210133106","https://openalex.org/I4210156109"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Diego Saldana","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Diego Saldana","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111976833","display_name":"Nico Janssens","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nico Janssens","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112068105","display_name":"M.M. Balp","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Maria-Magdalena Balp","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109255209","display_name":"Sam Khalil","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Sam Khalil","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083796664","display_name":"Val\u00e9ry Risson","orcid":"https://orcid.org/0000-0001-9597-8797","observed_orcids":["https://orcid.org/0000-0001-9597-8797"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Val\u00e9ry Risson","raw_affiliation_strings":["Novartis Pharma AG, Basel, Switzerland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharma AG, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":8,"corresponding_author_ids":["https://openalex.org/A5014026287"],"corresponding_institution_ids":["https://openalex.org/I4210112085","https://openalex.org/I4210135003"],"apc_list":{"value":4000,"currency":"USD","value_usd":4000},"apc_paid":{"value":4000,"currency":"USD","value_usd":4000},"fwci":6.0638,"has_fulltext":true,"cited_by_count":51,"citation_normalized_percentile":{"value":0.96841725,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"6","issue":"4","first_page":"1191","last_page":"1197.e5"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12438","display_name":"Urticaria and Related Conditions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12438","display_name":"Urticaria and Related Conditions","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2708","display_name":"Dermatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11346","display_name":"Mast cells and histamine","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12600","display_name":"Eosinophilic Disorders and Syndromes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-spontaneous-urticaria","display_name":"chronic spontaneous urticaria","score":0.9940000176429749},{"id":"https://openalex.org/keywords/omalizumab","display_name":"omalizumab","score":1.0},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.8939999938011169},{"id":"https://openalex.org/keywords/symptom-recurrence","display_name":"symptom recurrence","score":0.8379999995231628},{"id":"https://openalex.org/keywords/predictors-of-relapse","display_name":"predictors of relapse","score":0.8640000224113464},{"id":"https://openalex.org/keywords/urticaria-activity-score","display_name":"urticaria activity score","score":0.8880000114440918},{"id":"https://openalex.org/keywords/early-treatment-response","display_name":"early treatment response","score":0.7630000114440918},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C2778564945","wikidata":"https://www.wikidata.org/wiki/Q415392","display_name":"Omalizumab","level":4,"score":0.9390676021575928},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.8240026235580444},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7892632484436035},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7444722652435303},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5043753385543823},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4744330942630768},{"id":"https://openalex.org/C1862650","wikidata":"https://www.wikidata.org/wiki/Q186005","display_name":"Physical therapy","level":1,"score":0.34130629897117615},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.08220717310905457},{"id":"https://openalex.org/C141105273","wikidata":"https://www.wikidata.org/wiki/Q79455","display_name":"Immunoglobulin E","level":3,"score":0.06752604246139526},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.06623479723930359},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000069444","descriptor_name":"Omalizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002908","descriptor_name":"Chronic Disease","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012008","descriptor_name":"Recurrence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014581","descriptor_name":"Urticaria","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018926","descriptor_name":"Anti-Allergic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1016/j.jaip.2018.04.003","doi":"https://doi.org/10.1016/j.jaip.2018.04.003","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jaip.2018.04.003","pdf_url":"http://www.jaci-inpractice.org/article/S2213219818302733/pdf","source":{"id":"https://openalex.org/S2754868259","display_name":"The Journal of Allergy and Clinical Immunology In Practice","issn_l":"2213-2198","issn":["2213-2198","2213-2201"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Allergy and Clinical Immunology: In Practice","raw_type":"journal-article"},{"id":"pmid:29655772","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/29655772","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The journal of allergy and clinical immunology. In practice","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:recercat.cat:2072/356846","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10230/41655","pdf_url":null,"source":{"id":"https://openalex.org/S4306402147","display_name":"RECERCAT (Consorci de Serveis Universitaris de Catalunya)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210090028","host_organization_name":"Consorci de Serveis Universitaris de Catalunya","host_organization_lineage":["https://openalex.org/I4210090028"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:dadun.unav.edu:10171/65812","doi":null,"is_oa":true,"landing_page_url":"https://hdl.handle.net/10171/65812","pdf_url":"https://dadun.unav.edu/bitstreams/1482f940-253a-4964-9c86-50746b49817f/download","source":{"id":"https://openalex.org/S4306401514","display_name":"Deposito Adademico Digital Universidad De Navarra (University of Navarra)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I88155538","host_organization_name":"Universidad de Navarra","host_organization_lineage":["https://openalex.org/I88155538"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:repositori.upf.edu:10230/41655","doi":null,"is_oa":true,"landing_page_url":"http://hdl.handle.net/10230/41655","pdf_url":null,"source":{"id":"https://openalex.org/S4306402615","display_name":"Repositori digital de la UPF (Universitat Pompeu Fabra)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I170486558","host_organization_name":"Universitat Pompeu Fabra","host_organization_lineage":["https://openalex.org/I170486558"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.jaip.2018.04.003","doi":"https://doi.org/10.1016/j.jaip.2018.04.003","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jaip.2018.04.003","pdf_url":"http://www.jaci-inpractice.org/article/S2213219818302733/pdf","source":{"id":"https://openalex.org/S2754868259","display_name":"The Journal of Allergy and Clinical Immunology In Practice","issn_l":"2213-2198","issn":["2213-2198","2213-2201"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of Allergy and Clinical Immunology: In Practice","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320332193","display_name":"Genentech","ror":"https://ror.org/04gndp242"},{"id":"https://openalex.org/F4320332736","display_name":"Novartis Pharma","ror":"https://ror.org/0013shd50"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2797228551.pdf","grobid_xml":"https://content.openalex.org/works/W2797228551.grobid-xml"},"referenced_works_count":41,"referenced_works":["https://openalex.org/W1569638557","https://openalex.org/W1650397053","https://openalex.org/W1787157457","https://openalex.org/W1892482919","https://openalex.org/W1923203539","https://openalex.org/W1926061940","https://openalex.org/W1934538537","https://openalex.org/W1943323225","https://openalex.org/W1968667225","https://openalex.org/W2005758997","https://openalex.org/W2016519129","https://openalex.org/W2026119244","https://openalex.org/W2047251211","https://openalex.org/W2057677742","https://openalex.org/W2085071459","https://openalex.org/W2085255857","https://openalex.org/W2095710479","https://openalex.org/W2095966468","https://openalex.org/W2121663010","https://openalex.org/W2127438775","https://openalex.org/W2127951211","https://openalex.org/W2131291377","https://openalex.org/W2135046866","https://openalex.org/W2156152702","https://openalex.org/W2165948492","https://openalex.org/W2172185584","https://openalex.org/W2216062768","https://openalex.org/W2259918059","https://openalex.org/W2336873088","https://openalex.org/W2400798468","https://openalex.org/W2402139063","https://openalex.org/W2517879374","https://openalex.org/W2534434153","https://openalex.org/W2555644081","https://openalex.org/W2556598798","https://openalex.org/W2591394776","https://openalex.org/W2596128663","https://openalex.org/W2596834113","https://openalex.org/W2785762210","https://openalex.org/W2810953097","https://openalex.org/W4294541781"],"related_works":["https://openalex.org/W2545400279","https://openalex.org/W4240263038","https://openalex.org/W4416323096","https://openalex.org/W4200204223","https://openalex.org/W4394840577","https://openalex.org/W4415685651","https://openalex.org/W7214281511","https://openalex.org/W4402831761","https://openalex.org/W4408040693","https://openalex.org/W2811419663"],"abstract_inverted_index":{"BACKGROUND:":[0],"Omalizumab":[1],"is":[2],"highly":[3],"effective":[4],"in":[5,252],"controlling":[6],"chronic":[7],"spontaneous":[8],"urticaria":[9,188],"(CSU)":[10],"symptoms;":[11],"however,":[12],"patients":[13,29,253],"can":[14,261],"experience":[15,31],"symptom":[16,32,52,112,185,231,250],"return":[17,53,113,232,251],"on":[18,265],"treatment":[19,117,258,270],"discontinuation.":[20],"Pivotal":[21],"clinical":[22],"trials":[23],"have":[24],"identified":[25],"2":[26,176],"categories":[27],"of":[28,40,48,51,77,97,111,164,184,223,229,248],"who":[30,256],"return:":[33,186],"rapid":[34,230,249],"and":[35,86,124,136,195,217,237,268],"slow.":[36],"OBJECTIVE:":[37],"The":[38,120],"objective":[39],"this":[41],"study":[42],"was":[43,130,139,146],"to":[44,108,132],"identify":[45,109],"potential":[46],"predictors":[47,110,183],"the":[49,151,180,199,205,246],"speed":[50],"after":[54,114],"stopping":[55,115],"omalizumab":[56,78,98,116,165,260],"treatment.":[57],"METHODS:":[58],"Phase":[59],"III":[60,154],"randomized":[61],"controlled":[62],"trial":[63],"(RCT)":[64],"data":[65,149],"from":[66,150],"ASTERIA":[67,87],"I":[68],"(n":[69,89,156],"=":[70,90,157],"319;":[71],"6":[72,159],"\u00d7":[73,93,160],"4":[74,94,161],"weekly":[75,95,162],"injections":[76,96,163],"75,":[79,99],"150,":[80,100],"300":[81,101,166],"mg":[82,167],"or":[83,103,168],"placebo;":[84,104,169],"NCT01287117)":[85],"II":[88],"323;":[91],"3":[92],"mg,":[102],"NCT01292473)":[105],"were":[106,177],"pooled":[107],"(16-week":[118],"follow-up).":[119],"least":[121],"absolute":[122],"shrinkage":[123],"selection":[125],"operator":[126],"regularization":[127],"regression":[128],"model":[129,181],"used":[131],"select":[133],"predictive":[134],"variables,":[135],"relapse":[137],"probability":[138,228,247],"represented":[140],"using":[141,148],"heatmap":[142],"visualizations.":[143],"Model":[144],"accuracy":[145],"tested":[147],"GLACIAL":[152],"phase":[153],"RCT":[155],"336;":[158],"NCT0126493).":[170],"RESULTS:":[171],"Of":[172],"746":[173],"variables":[174],"assessed,":[175],"selected":[178],"by":[179,203],"as":[182],"baseline":[187,215,235,266],"activity":[189],"score":[190],"over":[191],"7":[192],"days":[193],"(UAS7)":[194],"early":[196,269],"area":[197],"above":[198],"curve":[200],"(AAC;":[201],"determined":[202],"plotting":[204],"UAS7":[206,216,219,236,239,267],"scores":[207],"across":[208],"time":[209],"points).":[210],"Results":[211],"suggest":[212,244],"that":[213,245],"high":[214,238],"low":[218,234],"AAC":[220],"(slow":[221],"decrease":[222],"symptoms)":[224],"indicate":[225],"a":[226],"higher":[227],"than":[233],"AAC.":[240],"CONCLUSIONS:":[241],"These":[242],"results":[243],"with":[254,259],"CSU":[255],"discontinue":[257],"be":[262],"estimated":[263],"based":[264],"response.":[271]},"counts_by_year":[{"year":2026,"cited_by_count":5},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":7},{"year":2013,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2018-04-24T00:00:00"}